show the distribution of adult heights of isolated GHD (IGHD) cases after GH treatment from the database of the Foundation for Growth Science (FGS) in Japan and the National Children's Hospital (NCH). Fifty-nine percent of isolated GHD boys reached a height of 160 cm or more, while the ratio of girls who reached an adult height of 150 cm or more was 36% and 24%, at the respective institutions. This result indicates that it is extremely difficult especially for GHD girls to reach an adult height of 150 cm or more. The influencing factors on adult height are height SD scores at the start of GH treatment, therapeutic dose and the height at the onset of puberty in GHD treatment.
Dr. Itsuro Hibi reported the results of c o m b i n e d t r e a t m e n t o f G H a n d g o n a d a l suppressive agents for the first time in 1989 (1) . In his report, GH treatment alone was continued in cases with a height of approximately 135 cm at the onset of puberty and a gonadal suppressive agent was added to cases with a height of approximately 130 cm at onset of puberty in boys (Fig. 2) . Combination treatment was continued for four years on average in both boys and girls. IGHD boys with combination treatment showed greater pubertal height gain than IGHD boys with GH treatment alone. The same result was observed in girls (1) .
Empirical evidence supporting LHRH analog (LHRHa) treatment is as follows: 1) patients with eunuchoidism are tall; 2) men with estrogen receptor abnormalities (2) and aromatase deficiency (3) continuously grow without epiphyseal closure even after reaching 20 years of age and a height over 2 m; 3) of two siblings with testicular feminization syndrome, the one who received delayed estrogen replacement due to a gonadectomy reached a taller adult height than the other who showed spontaneous pubertal development without gonadectomy (4); and 4) patients with Turner's syndrome who receive estrogen therapy at an older age achieve taller adult height than those who receive it at a younger age (5).
As shown previously, approximately 40% of GHD boys do not reach an adult height of 160 cm after receiving GH treatment and approximately 70% of GHD girls do not reach an adult height of 150 cm after receiving growth hormone treatment. To better manage this situation, we analyzed the relation of height at onset of puberty and adult height in 29 boys and 29 girls with GHD treated at the National Children's Hospital/the N a t i o n a l C e n t e r f o r C h i l d H e a l t h a n d Development, Nose clinic, Kanagawa Children's Medical Center and Hiroshima Red Cross Hospital. Figure 3 shows height at onset of puberty and adult height of GH-treated boys. Circle symbols show GH-treated boys whose adult heights exceeded 160 cm and square symbols show GH-treated boys whose adult heights were below 160 cm. In boys, when a cut-off value for adult height of 160 cm or more is set, the height at the onset of puberty is 135cm or more; the sensitivity is 93% (13/14) and the specificity is 67% (10/15). In other words, most boys who enter puberty (4 ml of testis volume) with a height of 135 cm or higher will reach an adult height of 160 cm or more, whereas two thirds of boys with a pubertal height of less than 135 cm will not reach an adult height of 160 cm (Fig. 3) . Figure 4 shows height at onset of puberty and adult height of GHtreated girls. Circle symbols show GH-treated girls whose adult heights exceeded 150 cm and square symbols show GH-treated girls whose adult heights were below 150 cm. In girls, when a cutoff value for adult height of 150 cm or more is set, the height at the onset of puberty is 133 cm; the sensitivity is 63% (5/8) and the specificity is 90% (19/21) (Fig. 4) . Thus, boys with a pubertal height of less than 135 cm and girls with a pubertal height of less than 133 cm should be given combination therapy of LHRHa and GH, since it is highly likely that they will fall short of adult heights of 160 cm and 150 cm in boys and girls, respectively. Twenty-six boys who were less than 135 cm at the onset of puberty were administered GH/ LHRHa combination therapy. The mean chronological age at the start of LHRHa was 12.2 years old, the mean height 132.9 cm, and the mean bone age 11.1 years old ( Table 1) . As a result, 23 When the height at onset of puberty was compared between boys with combination treatment and boys who entered puberty below 135 cm and received GH treatment alone, it was shorter in the combination group (127.6 cm on average) than that GH alone group (132.1 cm on average) though the difference was not significant (Table 1) . However, the height at the cessation of the treatment tended to be taller in the combination treatment group (160.8 cm on average) than the GH alone group (158.4 cm on average). In addition, the combination treatment group gained more than 3 cm in height even after the cessation of GH treatment due to their younger bone age (Table 2) . Finally, 33% of the GH alone group reached an adult height taller than 160 cm, while 88% of the combination treatment group exceeded 160 cm in adult height. The mean pubertal growth was significantly greater in the combination treatment group (36.3 cm on average) than that of GH alone group (27.0 cm on average) (Fig. 5) .
Similarly in girls who enter puberty at heights less than 133 cm, 21 cases in the GH treatment g r o u p a n d n in e c a s e s i n t he G H / L H R H a combination treatment group were compared (Tables 3, 4). As in the case of boys, the girls in the combination treatment group, who were younger at the onset of puberty and shorter than the GH In addition, they gained height after the cessation of GH treatment and 67% (6/9) of them reached an adult height taller than 150 cm. In the GH treatment group, only 10% (2/21) reached an adult height taller than 150 cm. The pubertal growth in t h e c o m b i n a t i o n t r e a t m e n t g r o u p w a s approximately 29.9 ± 5.7 cm, whereas that in the GH treatment group was 19.7 ± 5.3 cm, which is almost the same as the pubertal growth of untreated short girls (Fig. 6 ). In summary, among GH-treated children who entered puberty at a short height, patients administered with combination treatment displayed a significantly taller adult height as well as higher ratio of normal adult height compared with patients administered GH treatment alone. However, the ratio of the girls with normal adult height was smaller than that of the boys. The 
Discussion
Tachibana: Pubertal ages are an extremely important period when bone mineral density increases. What impacts will be exerted at later stages by inhibiting sex hormones that r e p o r t e d l y p r o m o t e m i n e r a l d e n s i t y accumulation during that period? While it may present fewer problems in the case of precocious puberty, where bone mineral density (BMD) is originally slightly higher for age, doesn't lowering of BMD, which is normal for age, by LHRHa therapy pose any problems in the case of a relatively precocious puberty, where the BMD i s n o r m a l f o r a g e , b u t s e c o n d a r y s e x characteristics appear early for height? Many studies report that BMD lowered or did not increase sufficiently during gonadal suppression therapy. In addition, some studies report that bone mineral density was lowered as a result of a transient disease such as anorexia nervosa and delayed puberty will not catch up with the normal bone density even after recovery from the disease. Bone mineral density is difficult to assess because it differs significantly among individuals but I suggest that gonadal suppression therapy needs to be properly followed up. What findings have been revealed in relation to bone mineral density in the data of Dr. Tanaka?
Fig. 6 Comparisone of pubertal growth between GH Tx and combination Tx in girls
Tanaka: At our Center, all cases have reached their full pubertal maturation at least two years after the cessation of LHRHa. However, none of them have reached 0 SD in BMD (DEXA method). With BMD limited to -0.5 to -2 SD for boys and -1.5 to -2.5 SD for girls, they need to be continuously followed up.
Tachibana:
The next problem is the possibility of persistent hypogonadism. Improvement in adult height by gonadal suppression therapy needs a long period, during which a patient will be left in a state of hypogonadotropic hypogonadism. During this period, a histologic change may occur in the sexual glands as seen in animal experiments. In addition, impacts from complete inhibition of gonadotrophin secretion and hypogonadism, due to anti-LHRH antibody formation, are theoretically likely to occur and precautions are needed. I will show you data summarized on the occasion of a clinical trial conducted in Japan in association with recovery of post-treatment gonadal functions. Significant recovery was seen in the blood LH level and estradiol level within three months after gonadal suppression therapy. In addition, the data also indicates that breast development and genital bleeding also recovered favorably (Fig. 1) .
How about fertility? According to a report of Murram et al. (1984) concerning 42 untreated cases with sporadic precocious puberty (aged 15 to 37 yr old with ages of onset ranging from 1 to 8 yr old), 40 cases of the 42 cases were normal in menstrual cycle, nine cases of which were married, eight cases of which had delivered 14 sound children, and one case of which was infertile. The infertility ratio is considered to be almost the same as the ratio in the general population. A report by Feuillan et al. (1999) observed gonadal functions of 32 cases with sporadic precocious puberty and 18 cases with hamartoma who took LHRHa therapy (for a period ranging from 3.1 yr to 10.3 yr). Seven cases (including three cases with hamartoma) of the above cases experienced eight pregnancies including five normal deliveries, two artificial abortions and one natural abortion due to complication of diabetes. Thus, the data shows results which are not bad for recovery after LHRHa treatment.
Tanaka:
The age of menarche in girls who received GH/LHRHa combination treatment in our Center is 15.6 yr old on average. Although all the girls experienced menarche within 
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Vol.14 / Suppl 24 approximately 1.4 yr after the cessation of the combination therapy on average, it is apparent that the age at menarche is delayed compared with the girls in the GH treatment group (the average age of menarche 13.2 yr old).
Tachibana: While gonadal functions may significantly recover after the LHRHa treatment, a cause-and-effect relationship with gonadal suppression therapy cannot be den ied completely, should a patient become infertile after the treatment. Thus sufficient informed consent will be needed before administering the therapy to patients.
In addition, such allergic symptoms as flare, urticaria, and anaphylaxis have been reported as side effects of LHRHa. It should always be kept in mind that LHRHa may cause such side effects.
Gonadal suppression therapy can have several detrimental effects on the mental aspects of patients. Firstly, gonadal suppression therapy for cases with short stature under growth hormone treatment will delay puberty in an artificial manner, viz., abnormalize originally normal puberty. Therefore it is considered difficult to continue the therapy unless patients themselves sufficiently accept the expected delay in their puberty. Secondly, I am sometimes told that patients are prone to withdraw while receiving the GH/LHRHa therapy. In the treatment of children with failure to thrive, I always feel that it is very often the parents of the patients who are more earnest in the patients' treatment rather than the patients themselves. It is ideal if patients can start to receive treatment at an age when they can accept the things based on a sufficient understanding of our explanation; however, in gonadal suppression therapy, patients must start to receive treatment before they are old enough to understand what's going on around them and must continue it until after they reach the age of discretion, around high school age or the like. Accordingly, such a problem arises when patients are prone to be easily controlled by their parents resulting in the extreme difficulty for them in maintaining their mental aspects favorably.
Thirdly, should the growth rate be lowered extremely due to the combination therapy with LHRHa, the situation may be unacceptable for the patient who has been taking painful injections with a desire to grow taller. Fourthly, patients may face a situation where their excessive desire for greater height was not satisfied. It is often the case that successful height growths to us doctors are not always satisfactory for patients or their parents. Thus, treatment needs to start after due explanation. However, I believe that it is often the case that, while gonadal suppression therapy is provided easily for children with short stature under growth hormone treatment in daily diagnosis and treatment on the grounds that the children reached puberty, patients themselves or the parents of the patients have excessive expectations, without a sufficient explanation provided, that the patients' height will grow without fail if they are treated. I believe precocious puberty of an infant is a disease itself; however, gonadal suppression therapy, in addition to growth hormone treatment, needs to be administered extremely carefully to children who are merely short without any serious diseases, because the above therapy will apply drugs that are safe but not always free from side effects. In my opinion, I would like to ask Dr. Tanaka to collect as many cases as possible to provide a certain direction for gonadal suppression therapy.
Tanaka:
We make it a rule to explain to patients about the matters shown in Table 5 before administering GH/LHRHa combination treatment to them. It is especially important how much patients have understood the relevant facts. Even if parents wish for the treatment, treatments will undoubtedly be stopped before completion if they are started without the consent of the patients themselves; therefore, we will not provide the treatment unless the patients themselves wish to receive the treatment. We will continue the treatment if patients wish to receive the treatment, no matter how young they might be. This point is extremely important. In addition, patients will be able to avoid psychosocial problems caused by delayed puberty with peers and they will be able to continue the treatment if they have a strong desire to grow taller. Thus, difficult problems can be avoided if patients have understood the treatment well enough. However, it is extremely difficult to receive agreement on those explanatory matters (Table 5 ) from patients and their parents. In my experience, the bone age decelerates under GH/LHRHa combination therapy after 11.5 yr of bone age in boys. However, the bone age will not stop completely but will slowly advance until 14 yr on average. Bone age will decelerate after 10.5 yr of bone age in girls but will slowly advance until reaching 13 yr of bone age. Since the pubertal growth spurt is dependent on the sex hormones, patients on gonadal suppression therapy do not show the normal pubertal spurt. Boys tend to keep a more stable growth rate than girls, however their g r o w t h r a t e i s l e s s t h a n n o r m a l b o y s . Accordingly, the poor growth spurt needs to be compensated by the length of treatment, and boys need long-term treatment for gonadal suppression therapy.
The above findings are summarized as follows: 1) The bone age will inevitably advance even under LHRHa treatment until 14 yrs in boys and 13 yr in girls.
2) The growth rate becomes difficult to maintain after 13.5 yr of bone age for boys and after 12 yr of bone age for girls. 3) While a boy will grow at least approximately 5 cm after completion of LHRHa treatment if his bone age is younger than 14 yr, a girl will not grow more than 1 to 2 cm if her bone age is 12.5 yr or more.
The GH/LHRHa combination treatment protocol currently revised at our Center is as shown in Table 6 . The growth rate will decrease with the gradual advance of bone age. Boys will significantly slow their growth rate after 13.5 yr of bone age and girls after 12 yr of bone age. The therapy becomes difficult to continue if the growth rate falls below 3 cm/yr. The time for completion of the therapy will be determined in accordance with the growth potential method in view of the patients' desired adult height; however, it is often the case that girls must discontinue their treatment before reaching their desired height.
In summary, when GH-treated children enter puberty with short stature, improvement of adult height can be expected with combination use of LHRH analog. However, it is necessary to explain Table 5 Explanation to patients and their parents before combination treatment • Combination treatment is not completely established and is still experimental.
• Combination treatment does not promise the desirable adult height.
• The patients will receive injections every month for at least 3 years.
• Psychosocial problems due to delayed puberty may develop.
• Pubertal maturation progress after cessation of LHRH analog, but it takes more than one or two years for girls to experience menarche.
• Long term follow-up is necessary for the occurrence of future osteoporosis.
• Unless the patients themselves wish strongly desire to receive the treatment, it will be difficult to continue the treatment. Vol.14 / Suppl 24 the necessity of long treatment and possible adverse reactions. Long term follow-up is necessary for recovery of gonadal function and bone mineral density after the cessation of treatment. Table 6 Protocol for GH and LHRH combination therapy
• Subjects Stature at onset of puberty: Males ≤ 135 cm, Females ≤ 133 cm Male and female subjects with adult stature of < 160 cm and < 150 cm after bone ages of 11.5 yr and 9.5 yr, estimated by the Growth Potential method, respectively • Initiation of therapy: Preferably after a growth spurt Males: After bone age of 11.5 yr (about 12 yr of age) Females: After bone age of 10.5 yr (about 11 yr of age)
• Start with 60 µg/kg leuplin administration
• Target levels: LH < 0.5 mU/mL, testosterone < 10 ng/dL, E2 < 10 pg/mL • Bone ages are evaluated at 3-6-mo intervals by the Japanese standard TW2 method, and for advanced bone ages, leuplin is increased.
